Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

emtricitabine (Rx)Brand and Other Names:Emtriva

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 200mg

oral solution

  • 10mg/mL
more...

HIV Infection

Capsule: 200 mg PO qDay

Oral Solution: 240 mg PO qDay

Renal Impairment

CrCl 50 mL/min or more: capsule 200 mg PO qDay; oral solution: 240 mg PO qDay

CrCl 30-49 mL/min: capsule 200 mg PO q48hr; oral solution: 120 mg PO qDay

CrCl 15-29 mL/min: capsule 200 mg PO q72hr; oral solution: 80 mg PO qDay

CrCl <15 mL/min: capsule 200 mg PO q96hr; oral solution: 60 mg PO qDay

Administration on day of hemodialysis: Administer after dialysis

Dosage Forms & Strengths

capsule

  • 200mg

oral solution

  • 10mg/mL
more...

HIV Infection

<3 months

  • Oral solution: 3 mg/kg PO qDay 

>3 months

  • Oral solution: 6 mg/kg PO qDay, no more than 240 mg
  • Capsules (if >33 kg): 200 mg (1 capsule) PO qDay

Renal Impairment

Reduce dose and/or increase dosing interval

Next

Interactions

Interaction Checker

emtricitabine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequencies based on combination treatment

            >10%

            Diarrhea (21-25%)

            Dizziness (21-25%)

            Headache (21-25%)

            Insomnia (21-25%)

            Rash (21-25%)

            Asthenia (16-20%)

            Nausea (16-20%)

            Rhinitis (16-20%)

            Abdominal pain (11-15%)

            Abnormal dreams (11-15%)

            Incr CK (11-15%)

            Incr cough (11-15%)

            Neuritis (11-15%)

            Paresthesia (11-15%)

            1-10%

            Depressive symptoms (6-10%)

            Dyspepsia (6-10%)

            Vomiting (6-10%)

            Incr triglycerides (6-10%)

            Myalgia (6-10%)

            <1%

            Lactic acidosis/severe

            Hepatomegaly with steatosis, including fatal cases; post treatment exacerbation of Hepatitis B

            Previous
            Next

            Warnings

            Black Box Warnings

            Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) reported with use of nucleoside analogues alone or in combination with other antiretrovirals

            Not FDA approved for treatment of chronic hepatitis B virus (HBV) infection, and the safety and efficacy of this drug have not been established in patients co-infected with HBV and HIV

            Contraindications

            Hypersensitivity

            Cautions

            (All NRTIs): Risk of potentially fatal lactic acidosis & severe hepatomegaly with steatosis when used alone or in combination with other antiretrovirals

            Risk of immune reconstitution syndrome if used in combination w/ other antiretroviral drugs

            Should not be coadministered with combination antiretroviral agents containing emtricitabine

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: It is not known whether emtricitabine is excreted in milk. It should not be administered to nursing mothers. The CDC advises HIV-infected women not to breast-feed to avoid postnatal transmission of HIV.

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Nucleoside Reverse Transcriptase Inhibitor (NRTI); cytosine analog phosphorylated to emtricitabine 5'-triphosphate caucing inhibition of HIV and RNA dependent DNA polymerase

            Pharmacokinetics

            Bioavailability: 93%

            Protein Bound: <4%

            Metabolism: Oxidation

            Dialyzable: 30% removed by hemodialysis

            Excretion: Urine (86%); feces (14%)

            Half-Life: 10 hr

            Peak PlasmaTime: 1-2 hr

            Concentration: 1.8±0.7 mcg/m

            LAUC: 10±3.1 hr.mcg/mL

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.